Comparative Effectiveness Research
Our health care consultants have worked collaboratively with clients in the life sciences field to perform comparative effectiveness research. We have examined the costs and value of therapies used to combat a range of diseases and have amassed a comprehensive database of outcomes evidence in the process.
Our research relates the clinical outcomes of treatment alternatives to their economic profiles. We evaluate the pharmacoeconomic profile of interventions using data from multiple sources, including:
- Administrative claims
- Epidemiologic surveys
- Registry data
- Electronic medical records
- Chart review
- Clinical trials
- Market research
We assess the impacts of these interventions in terms of cost, quality-adjusted life years, and clinical effectiveness to make comparisons across alternative therapies and disease states.
Selected Examples of Our Work
- Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E. Societal Economic Benefits Associated with an Extended-Release Opioid with Abuse-Deterrent Technology in the United States. Pain Medicine. 2014, 15(9), 1450–1454.
- Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Budget Impact Analysis of Everolimus for the Treatment of Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative (HER2-) Advanced Breast Cancer in the United States. Journal of Medical Economics. 2013, 16(2), 278–288.
- Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder MH, Dammerman R, Robertson B, Wu EQ. Comparative Treatment Patterns, Resource Utilization, and Costs in Stimulant-Treated Children with ADHD Who Require Subsequent Pharmacotherapy with Atypical Antipsychotics Versus Non-Antipsychotics. J Manag Care Pharm. 2012; 18, 9, 676–689.
- Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW. Duloxetine Use in Chronic Low Back Pain: Treatment Patterns and Costs. PharmacoEconomics. 2012: 30 (7):595–609.
- Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL. A Model to Identify Patients at Risk for Prescription Opioid Abuse, Dependence, and Misuse. Pain Medicine. 2012; 13(9), 1162–1173.
- Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guérin A, Boerstoel-Streefland M, Jiang W, Lefebvre P. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. Annals of Pharmacotherapy. 2011; 45(2), 179–188.
- Signorovitch J, Birnbaum H, Ben-Hamadi R, Yu AP, Kidolezi Y, Kelley D, Phillips G, Lawson A, Ball DE. Increased Olanzapine Discontinuation and Health Care Resource Utilization Following a Medicaid Policy Change. The Journal of Clinical Psychiatry. 2011; 72(6), 787–794.
